<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20155">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844517</url>
  </required_header>
  <id_info>
    <org_study_id>19068</org_study_id>
    <secondary_id>UC4DK108483</secondary_id>
    <nct_id>NCT02844517</nct_id>
  </id_info>
  <brief_title>International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol</brief_title>
  <official_title>Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial Research Site Training Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TypeZero Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tandem Diabetes Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostic Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ascensia Diabetes Care</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is for clinical staff to gain experience using the proposed
      artificial pancreas system named inControl and the inControl Cloud and assess 24/7 in-home
      usability prior to initiating a large randomized controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation in this study will require 5 study visits over 2-4 weeks.

        -  Visit 1: screening/enrollment visit to assess study eligibility.

        -  Visit 2: continuous glucose monitor (CGM) training and initiation session based upon
           current or prior use of a CGM; if subject doesn't currently use a CGM, subject will be
           trained and may be asked to wear the CGM at home for 1 week.

        -  Visit 3: subjects will be taught how to use the study insulin pump.

        -  Visit 4: subjects will be trained on the use of inControl and wear it at home for 14
           days.

        -  Visit 5: subjects will return study equipment and to complete questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Artificial Pancreas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artificial Pancreas</intervention_name>
    <description>Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.</description>
    <arm_group_label>Artificial Pancreas</arm_group_label>
    <other_name>inControl Diabetes Medical Platform</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
             one year and using insulin for at least 1 year

          2. Use of an insulin pump for at least 6 months with established parameters for basal
             rate(s), carbohydrate ratio(s) and insulin sensitivity factor(s) for at least 3
             months.

          3. Age 14.0 to &lt;75.0 years

          4. HbA1c level &lt;10.5% at screening

          5. For females, not currently known to be pregnant. If female and sexually active, must
             agree to use a form of contraception to prevent pregnancy while a participant in the
             study. A negative serum or urine pregnancy test will be required for all
             premenopausal women who are not surgically sterile. Subjects who become pregnant will
             be discontinued from the study. Also, subjects who during the study develop and
             express the intention to become pregnant within the timespan of the study will be
             discontinued.

          6. Have care partner committed to participating in all training activities,
             knowledgeable at all times of the participants location, and being present and
             available to provide assistance when the system is being used at night

          7. Willingness, if using the closed-loop system, to stop closed-loop when taking
             acetaminophen and avoid closed-loop for at least 4 hours afterward

          8. Willingness to suspend use of any personal CGM for the duration of the clinical trial
             once the study CGM is in use

          9. Willingness to establish network connectivity on a daily basis either via local Wi-Fi
             network or via a study-provided cellular service

         10. Investigator has confidence that the subject can successfully operate all study
             devices and is capable of adhering to the protocol

         11. Currently using no insulins other than one of the following rapid-acting insulins at
             the time of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or
             insulin glulisine (Apidra)

        Exclusion Criteria

          1. More than one episode of diabetic ketoacidosis (DKA) in the 6 months prior to
             enrollment

          2. More than one episode of severe hypoglycemia involving seizure of loss of
             consciousness in the 6 months prior to enrollment

          3. Medical need for chronic acetaminophen

          4. Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists,
             Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and
             naturaceuticals).

          5. Hemophilia or any other bleeding disorder

          6. A condition, which in the opinion of the investigator or designee, would put the
             participant or study at risk

          7. Participation in another pharmaceutical or device trial at the time of enrollment or
             during the study

          8. Employed by, or having immediate family members employed by TypeZero Technologies,
             LLC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris P. Kovatchev, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Center for Diabetes Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacey M. Anderson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia Center for Diabetes Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacey M. Anderson, MD</last_name>
    <phone>434-982-0945</phone>
    <email>sg4c@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emma Emory, RN</last_name>
    <phone>434-243-3992</phone>
    <email>ee9m@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>William Sansum Diabetes Center</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Pinsker, MD</last_name>
      <email>jpinsker@sansum.org</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Burke</last_name>
      <phone>805-682-7638 ext 221</phone>
      <email>kburke@sansum.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jordan Pinsker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mei Mei Church, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Buckingham, MD</last_name>
      <phone>650-723-5791</phone>
      <email>bbendo@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eliana Frank</last_name>
      <phone>650-736-6642</phone>
      <email>elianaf@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bruce Buckingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center, University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Paul Wadwa, MD</last_name>
      <phone>303-724-2323</phone>
      <email>paul.wadwa@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Jost, MPH RD CDE</last_name>
      <phone>303-724-7313</phone>
      <email>emily.jost@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>R. Paul Wadwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harvard University (Joslin Diabetes Center)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Laffel, MD, MPH</last_name>
      <phone>617-732-2603</phone>
      <email>lori.laffel@joslin.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Louise Ambler-Osborn, CPNP</last_name>
      <phone>617-732-2603</phone>
      <email>louise.ambler-osborn@joslin.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Francis Doyle, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lori Laffel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yogish Kudva, MBBS, M.D.</last_name>
      <phone>507-284-3964</phone>
      <email>kudva.yogish@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shelly McCrady-Spitzer</last_name>
      <phone>507-255-5916</phone>
      <email>mccradyspitzer.shelly@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Yogish Kudva, MBBS, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ananda Basu, MBBS, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Levy, MD, CDE</last_name>
      <phone>212-241-9089</phone>
      <email>selassie.ogyaadu@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Camilla Levister, ANP-C, MS</last_name>
      <phone>212-241-5177</phone>
      <email>Camilla.Levister@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carol Levy, MD, CDE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Lam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey M. Anderson, MD</last_name>
      <phone>434-982-0945</phone>
      <email>sg4c@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Emory, RN</last_name>
      <phone>434-243-3992</phone>
      <email>ee9m@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stacey Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sue Brown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Renard, MD, PhD</last_name>
      <phone>+33-04 67 33 84 24</phone>
      <email>e-renard@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jerome Place</last_name>
      <phone>+33 618 261 610</phone>
      <email>jerome.place@umontpellier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Renard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Farret, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Cobelli, PhD</last_name>
      <phone>+39-049-8277803</phone>
      <email>cobelli@dei.unipd.it</email>
    </contact>
    <contact_backup>
      <last_name>Simone Del Favero, PhD</last_name>
      <phone>+39 049 827 7661</phone>
      <email>sdelfave@dei.unipd.it</email>
    </contact_backup>
    <investigator>
      <last_name>Claudio Cobelli, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Bruttomesso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Hans DeVries, MD, PhD</last_name>
      <phone>+3120 5666525</phone>
      <email>j.h.devries@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Masurel, MSc</last_name>
      <phone>+31 205 666 473</phone>
      <email>N.masurel@amc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>J Hans DeVries, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 20, 2017</lastchanged_date>
  <firstreceived_date>July 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Stacey Anderson</investigator_full_name>
    <investigator_title>Study Chair</investigator_title>
  </responsible_party>
  <keyword>Artificial Pancreas</keyword>
  <keyword>Closed Loop Control</keyword>
  <keyword>Continuous Glucose Monitor (CGM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Not yet determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
